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ABSTRACT
lucose intolerance (GI) is a state of abnormal 
glucose metabolism in which Impaired Gglucose tolerance (IGT) and impaired fasting 
glucose (IFG) are intermediate stages in the natural 
1
history of diabetes mellitus.  Impaired glucose 
tolerance is defined as two-hour glucose levels of 140-
199mg/dl (7.8-11.0mmol/l) on the 75-g oral glucose 
tolerance test (OGTT), and Impaired fasting glucose is 
defined as glucose levels of 100-125mg/dl (5.6-
6.9mmol/l) in fasting patients. Patients with IGT and 
IFG have a significant risk of developing diabetes and 
cardiovascular morbidity and mortality, thus are an 
important target group for primary prevention.
In published data from North America and Western 
European populations, between 10 and 20% of adults 
(25 years and above) have IGT based on OGTT with a 




The advent of potent antiviral drugs has revolutionalised the clinical course of HIV / AIDS resulting in increased 
survival and improved quality of life. Metabolic derangements in HIV infected patients are becoming more common 
probably due to this increased survival from the use of HAART. There is limited data on the occurrence of glucose 
intolerance among HIV patients in Nigeria.
OBJECTIVE
To determine the prevalence of glucose intolerance and associated risk factors in HIV/AIDS patients.
METHODS
Consenting adult HIV patients at the HIV clinic of the Jos University Teaching Hospital (JUTH), Jos , Nigeria were 
evaluated were evaluated for the presence of glucose intolerance using a 75g oral glucose tolerance test (OGTT). 
There clinical characteristics, anthropometry, CD4 cell counts and viral load were determined using appropriate 
standard techniques. Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), and Diabetes Mellitus 
(DM) were defined based on the American Diabetes Association (ADA) cut-off values. 
RESULTS
Of the 584 patients studied, 384 (130 males and 251 females) with mean±SD age of 38±15 years were HAART-
treated; while 200 (61 males and 139 females) with mean±SD age of 33±17 years were HAART-naive. Overall, the 
prevalence of GI was 40.4% (IFG) 19.5%, IGT 11.5% and DM 9.4%. The prevalence of IFG (27.1%) and DM (11.2%) in 
HAART - treated patients were observed and those in HAART-naive patients were (IFG 5.0%,DM 6.0%), p<0.005. 
IGT was more prevalent in HAART-naive than in HAART-treated patients (19.5%, and 7.3% respectively), p<0.05. 
The proportions of patients with GI were higher in overweight and obese HAART-treated patients with moderate 
CD4 cell count (200-500 x10  cell/L); while in the HAART-naive patients, GI was more prevalent in underweight 
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subjects with CD4 cell count (<200 x 10  cell/L). The Determinants of GI were age, increasing BMI, low CD4 cell 
count, metabolic syndrome and HAART treatment duration. The independent predictors of glucose intolerance in 
HIV / AIDS patients were low CD4 cell count and prolonged HAART treatment duration.
CONCLUSION: 
The prevalence of GI among HIV/AIDS patients in North-Central Nigeria is high. Treatment with HAART and low 
CD4 cell count are strong determinants of glucose intolerance in our HIV / AIDS patients. Regular screening for 
glucose intolerance among our HIV / AIDS patients is recommended. 
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The WHO guideline was used to classify waist 
circumference based on gender.  Blood pressure was 
measured using appropriate cuff sizes on both upper 
arms, one at a time under a calm and conducive 
environment with phase I and V Korotcoff recordings. 
The arm with the highest recording was taken as the 
subject's BP recording. The BP was defined by 
WHO/ISH guidelines.  Blood samples were taken in 
the morning after an overnight (8 – 12 hours) fast into 
appropriate specimen bottles for plasma glucose and 
lipid estimation. Each subject was prepared for an Oral 
Glucose Tolerance Test (OGTT) using 75g glucose 
based on standard laboratory procedures. Plasma 
glucose estimation was done using the glucose oxidase 
method of Trinder , while plasma lipids were 
determined using reagents contained in a kit      
(BIOLABO S. A. France). Plasma lipids determined 
include total cholesterol, HDL cholesterol and 
Triglycerides. The low density lipoprotein (LDL) 
cholesterol was calculated using Firedwald's formula.  
The diagnosis of IGT was made based on ADA 
diagnostic criteria for DM and intermediate glucose 
abnormalities.1 HIV testing, CD4 cell counts and viral 
load were determined using appropriate methods.
 
Statistical Analysis
Collated data was analyzed using EPI – INFO (version 
3.3.2). The student T-test was used for comparison of 
mean, while the Chi-squared test was used compare 
proportions. Multivariate analysis using logistic 
regression statistics was deployed to determine the 
independent risk factors for glucose intolerance. 
Statistical significance was defined as  p value < 0.05. 
RESULTS
Of the 584 patients studied, 384 (130 males and 254 
females) with mean±SD age of 38±15 years were 
HAART-treated (subjects); while 200 (61 males and 139 
females) with mean±SD age of 33±17 years were 
HAART-Naive (controls). Table 1 shows the details of 






having the condition.  There is a wide variation in the 
prevalence of IGT among different population in 
Africa.  In Tanzania, the prevalence was found to be 
about 10% in rural Bantu and 20% in Dar-es-Salam. 
Ohwovoriole et al  found a prevalence of 29.5% in a 
hospital based study from pooled data from two 
Diabetes clinics in Lagos.  
Human immunodeficiency virus (HIV) / Acquired 
immune deficiency Syndrome (AIDS) is a major health 
concern and cause of death in many parts of Africa. The 
continent is home to about 15.2% of the world's 
population,  sub-saharan Africa alone accounted for an 
estimated 69% of all people living with HIV(2)4new) 
and 70% 0f allAIDS deaths in 2011.  A 2013 special 
report issued by joint United Nation Programme on 
HIV/AIDS (UNAIDS) noted that the prevalence of 
HIV positive people in Africa receiving anti-retroviral 
treatment in 2012 was over seven times the number 
receieving treatment in 2005.  The 2011 prevalence rate 
in Nigeria was 3.7% within the Ages 15-49 years. It has 
been documented that along with improvement in well 
being and survival, patients with HIV/AIDS on 
HAART develop metabolic imbalances (IFG, IGT, DM 
and dyslipdeamia) more readily than the normal 
population.  In this study, we aimed to determine the 
prevalence of glucose intolerance and associated risk 
factors in HIV/AIDS patients in a specialist HIV / 
AIDS treatment centre. We also intend to add to the 
growing literature on the subject thus improving the 
paucity of data in Nigeria.
METHODS
This is a cross-sectional study carried out at the AIDS 
Prevention Initiative in Nigeria (APIN) clinic of the Jos 
University Teaching Hospital, Jos over an eleven 
month period. After obtaining ethical approval from 
the JUTH Research Ethics Committee, three hundred 
and eighty four consenting subjects (HIV sero-positive 
HAART treated), aged 15-70years were consecutively 
recruited. An age and sex matched control population 
of HIV sero-positive individuals (HAART naive) were 
selected from the same clinic after obtaining an 
informed consent. We obtained basic patient data such 
as age, gender, duration of HIV/AIDS, type and 
duration of treatment at the clinic and documented 
these in an interviewer-administered profoma.  
Physical examination carried out for all study 
participants included blood pressure, height, weight 
and waist circumference measurements. Body mass 
index (BMI) classified based on WHO guidelines.  The 
waist circumference (WC) was determined for each 
subject using a non-stretchable tailor's tape rule placed 
in a horizontal plane along the line of the umbilicus 



































































45 – 54 36(9.4) 36(9.4) 72(18.8) 10(5.0) 6(3.0) 16(8.0)
55 – 64 12(3.2) 3(0.8) 15(3.9) 6(3.0) 0(0) 6(3.0)
Total 130(33.9) 254(66.1) 384(100) 61(30.5) 139(69.5) 200(100)
Table 1: Age and Gender Distribution of Study Subjects and Controls
(6.5%), same was observed for obese (7.7%) in the study 
subject as compared to the control (0%) (P<0.05).
The anthropometric parameters of the subjects and 
controls are presented in Figure 1. The study subjects 
that were overweight (32%) were higher than in control 
Subjects  X2 = 44.5, p = 0.0001.                      Controls X2 =39.9, p <0.001
Figure 1: Body Mass Index (BMI) of Study Subjects Compared to Controls
Table 2: Prevalence of Glucose Intolerance among Study and Control Subjects
   Glucose  
Intolerance          Study
 
n(%)                  Control n(%)              Total
 
n(%)
             
P
IGT                            28(11.9)     
                 
39(16.5)
                      
67(28.4)
         
0.01
IFG
                            
104(44.1)                    10(4.2)                       114(48.3)
       
0.001
DM
                            
43(18.2)        
              
12(5.1)                       
 
55(23.3)
         
0.002
Total                       175(74.2) 61(25.8) 236(100.0)
IGT = Impaired Glucose Tolerance; IFG = Impaired Fasting Glucose; DM = Diabetes Mellitus
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study is shown in table 2. The plasma glucose cut off 
values used, are based on the American Diabetes 
1
Association position statement (ADA)
A total of 175 (45.6%) persons among the 384 HAART-
treated subjects were glucose intolerant, while 61 
(30.5%) of the 200 controls (HAART-naive) were 
glucose intolerant. The relative distribution of the 
various forms of glucose intolerance observed in this 
Table 3: Distribution of Glucose Intolerance in Study Subjects by CD4 Cell Count.
                                             Disease group by CD4 cell count (x106  cell/L)  
Glucose  
Intolerance         >500(%)           200-499(%)            <200(%)             P
 
IGT                       4(14.3                15(53.6)                  9(32.1)          
   
0.27
 
IFG                       13(12.5)             67(64.4)                  24(23.1)        
 
0.001
 DM                      4(9.3)                 29(67.4)                   10(23.3)         0.001
 
 
IGT = Impaired Glucose Tolerance; IFG = Impaired Fasting Glucose; DM = Diabetes Mellitus
Table 4 shows the distribution of glucose intolerance 
among control subjects based on CD4 cell count. The 
highest IFG (60%) was seen in the CD4 cell count range 
of 200 – 499x10  cell/L.
6
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Subjects with CD4 count 200 – 499 x 10 cell/L had the 
highest proportion of IFG (64.4%), IGT (53.6%) and DM 
(67.4%) as depicted in Table 3.
Table 4: Distribution of Glucose Intolerance in Control Subjects by CD4 Cell Count
                                             Disease group by CD4 cell count (x106  cell/L)
Glucose
 
Intolerance         >500(%)           
        
200-499(%)          
          
<200(%) P
IGT                     
     
0(0)
                            
10(25.6)     
                  
29(32.1)            0.001
IFG                      
   
1(10)  
                           
6(60)     
                        
3(30)               0.001
DM                    4(0)          0(0)                         12(100)             0.47
IGT = Impaired Glucose Tolerance; IFG = Impaired Fasting Glucose; DM = Diabetes Mellitus
treatment using anti-retrovirals was seen in subjects 
with IFG.  
Table 5 shows the distribution of glucose intolerance 
among the subjects based on HIV treatment duration. It 
appears a longer duration (longer than 48 months) of 
Table 5: Distribution of Glucose Intolerance in Subjects by Treatment Duration
                                             Treatment Duration (Months)  
Glucose  
Intolerance         12-24                 25-48             
          
>48                 P
 
IGT                      18(6.9)                5(7.4)                      5(9)                0.51
 
IFG                      60(23.0)              19(28)     
                
25(44.6)       0.001
DM                      20(7.7)               123(19.1)              10(17.8)         0.001
2
X = 52.0, p<0.001
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DISCUSSION
Advances in the antiretroviral therapy has led to 
prolonged survival and improved quality of life of 
HIV/AIDS infected patients with the development of 
metabolic derengments.
The prevalence of glucose intolerance among 
HIV/AIDS patients on HAART in this study was 
(45.6%) with IFG (27%) being highest in the study 
subjects and IGT (19.5%), DM (19.6%) in the controls. 
14
This is comparable to previous reports by YaraSheski  
who observed that up to 40% of HIV infected patients 
with lipodystrophy had impaired glucose tolerance or 
diabetes mellitus diagnosed on an oral glucose 
tolerance test (OGTT). The pathogenic mechanisms 
underlying the fat redistribution and metabolic 
alterations are multifactorial. The factors related to 
HIV/AIDS infection and its treatment, mitochondrial 
dysfunction, cytokine activation related to immune 
reconstitution and individual genetic predisposition 
are aetiological.
Grinspoon  observed that 35% of HIV subjects had 
impaired glucose tolerance and 7% had diabetes. The 
prevalence of metabolic syndrome observed in our 
study was 18.5% which was similar with the finding of 
Carlos et al  with a prevalence rate of 17% which is all 
attributable to the Lipodystrophic changes seen in 
HIV/AIDS patients with increased risks of 
cardiovascular disease. An increasing prevalence of 
glucose intolerance and metabolic syndrome with 
increasing BMI was observed in this study, a finding 
consistent with previous studies . Obesity is strongly 
associated with insulin resistance and glucose 
tolerance.
The proportion of patients with glucose intolerance 
were higher in HAART treated patients with moderate 
CD4 cell count (200 – 499 x 10  cells/L) while in HAART 
Naive patients glucose intolerance was more prevalent 
in patient with low CD4 cell count (< 200 x 10  cells/L), 
thus similar to the findings of Carlos J et al, who 
observed more risk of metabolic syndrome with 
reference to glucose homeostasis. El-Sadr et al , also 
noted that lower CD4 cell count confers increased risk 
of insulin resistance as an important marker in the 
development of DM. It is likely that the observed 
increase in prevalence of DM in this cohort of HIV-
treated patients may result in increased occurrence of 
DM related complications similar to the non HIV DM 
population as reported in a recent Nigerian multicentre 
study by Uloko et al.    The HAART-experienced 
patient were also noted to have increased glucose 
intolerance and metabolic syndrome with prolonged 










a reported threefold increase incidence of self reported 
21
diabetes.  Leow et al  also noted similar finding. 
Regular screening for diabetes is essential for all 




The prevalence of glucose intolerance in the North-
central region is high. Treatment with HAART and low 
CD4 cell count are strong determinants. The 
availability of free treatment programs in Nigeria has 
transformed HIV/AIDS to a chronic disease, thus 
leading to the development of metabolic derengements 
(IFG, IGT and DM). More frequent monitoring using 
fasting plasma glucose or 2-hour plasma glucose from 
oral glucose tolerance test (OGTT) may be reasonable 
for patients who are at highest risk because of their 
family history, and/or lipodystrophy ,with the view to 
treat early all patient with these metabolic sequelae.
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